Страна: Мальта
Язык: английский
Источник: Medicines Authority
VINORELBINE TARTRATE
Strides Arcolab International Limited Unit 4, Metro Centre, Tolpits Lane, Watford, Hertfordshire, WD 189 SS, United Kingdom
L01CA04
VINORELBINE TARTRATE 10 mg/ml
CONCENTRATE FOR SOLUTION FOR INFUSION
VINORELBINE TARTRATE 10 mg/ml
POM
ANTINEOPLASTIC AGENTS
Withdrawn
2014-08-14
PACKAGE LEAFLET: INFORMATION FOR THE USER VINORELBINE STRIDES 10 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION Vinorelbine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor. IN THIS LEAFLET: 1. What Vinorelbine Strides is and what it is used for 2. Before you use Vinorelbine Strides 3. How to use Vinorelbine Strides 4. Possible side effects 5. How to store Vinorelbine Strides 6. Further information 1. WHAT VINORELBINE STRIDES IS AND WHAT IT IS USED FOR Vinorelbine Strides is used in the treatment of cancer and belongs to a group of medicines known as Vinca alkaloids. Vinorelbine Strides is used to treat certain types of lung cancer and breast cancer. 2. BEFORE YOU USE VINORELBINE STRIDES DO NOT USE VINORELBINE STRIDES • if you are allergic (hypersensitive) to vinorelbine, other Vinca alkaloids, or any of the other ingredients of this medicine (see section 6). • if you have or recently had serious infection or severe decrease in white blood cells (neutropenia) • if you have severe decrease in blood platelets. • if you are pregnant • if you are breast-feeding (breast-feeding should be discontinued during treatment with vinorelbine) • if you are a women of childbearing potential not using effective contraception • in combination with yellow fever vaccine This medicine is strictly for intravenous use only and should not Прочитать полный документ
Page 1 of 12 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Vinorelbine Strides 10 mg/ml concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml concentrate for solution for infusion contains 10mg vinorelbine equivalent to 13.85mg vinorelbine tartrate. Each 1 ml vial contains 10 mg vinorelbine (as tartrate). Each 5 ml vial contains 50 mg vinorelbine (as tartrate). For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion. Clear, colourless to slightly yellow solution with a pH of 3.3 to 3.8 Diluted product : the osmolarity of the diluted product is about 330 mOsm/l. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Vinorelbine is indicated in the treatment of: - Non-small cell lung cancer (stage 3 or 4). - As single agent to patients with metastatic breast cancer (stage 4), where treatment with anthracycline- and taxane containing chemotherapy has failed or is not appropriate. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For intravenous infusion only. Vinorelbine Strides 10 mg/ml concentrate for solution for infusion should be administered under the supervision of a physician with extensive experience in therapy with cytostatics. Strictly intravenous administration after appropriate dilution. Intra-thecal administration of vinorelbine may be fatal. Instructions for use and handling: refer to section 6.6. Vinorelbine Strides 10 mg/ml concentrate for solution for infusion may be administered by slow bolus (6-10 minutes) after dilution in 20-50 ml of normal saline or glucose 50 mg/ml (5%) solution or by a short infusion (20-30 minutes) after dilution in 125 ml of normal saline or glucose 50 mg/ml (5%) solution. Administration should always be followed with at least 250 Прочитать полный документ